- Details
- Rashid Sayyid and Zach Klaassen review a study concerning AR and PI3K genomic profiling of cell-free DNA to identify poor responders to Lutetium-177-PSMA among mCRPC patients. This therapy is approved for patients whose disease has progressed following prior chemotherapy and androgen receptor signaling inhibitor, based on two Randomized Control Trials (RCTs): VISION and TheraP. These RCTs, however...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the development and validation of a multi-institutional nomogram for predicting outcomes of PSMA-PET-Based Salvage Radiotherapy in recurrent Prostate Cancer cases. Noting that 30-50% of high-risk patients experience biochemical failure within five years of radical prostatectomy, Drs. Sayyid and Klaassen highlight the increasing use of PSMA-PET/CT for staging...
|
- Details
- Rashid Sayyid and Zach Klaassen engage in a discussion about a Journal of Clinical Oncology publication. The study validates a prognostic model for overall survival in men with chemotherapy naive mCRPC, showcasing its overall predictive measure with a time-dependent area under the curve of 0.75. They emphasize the model's applicability, initially developed by Dr. Susan Halabi, that incorporates ro...
|
- Details
- Rashid Sayyid and Zach Klaassen explore a study by Brian Cortese and Ruchika Talwar regarding potential savings through generic oncology drugs purchased via Mark Cuban's Cost Plus Drug Company (MCCPDC) compared to Medicare. The study focuses on the economic impacts of high-priced generic oncology drugs, the financial toxicity experienced by patients, and how MCCPDC can help mitigate these problems...
|
- Details
- In a discussion Rashid Sayyid and Zach Klaassen, they delve into a study comparing advanced molecular imaging and conventional imaging in detecting metachronous oligometastatic castrate-sensitive prostate cancer. The study used data from phase two trials, including the STOMP and ORIOLE trials, which established the oncologic benefits of metastasis-directed therapy for patients with metachronous ol...
|
- Details
- Rashid Sayyid and Zach Klaassen present the CONTACT-03 trial examining the combination of atezolizumab plus cabozantinib compared to cabozantinib monotherapy in patients with renal cell carcinoma (RCC) who have progressed following prior immune checkpoint inhibitor treatment. Dr. Sayyid discusses the evolution of treatment for advanced or metastatic RCC, highlighting the emergence of immune checkp...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the COSMIC-313 clinical trial, examining the use of cabozantinib, nivolumab, and ipilimumab in renal cell carcinoma treatment. Published in the New England Journal of Medicine, the study focuses on patients with locally advanced or metastatic clear cell carcinoma. The trial, a phase III randomized, double-blind, placebo-controlled study, encompassed approxim...
|
- Details
- Rashid Sayyid and Zach Klaassen analyze an ad hoc analysis from the VISION study, published in the Journal of Nuclear Medicine. The study investigates the agreement between readers in the interpretation of 68Ga-PSMA-11 PET/CT scans to determine patient eligibility for 177Lu-PSMA-617 Radioligand Therapy in the treatment of prostate cancer. They elaborate on the study's methodology, including the re...
|
- Details
- Rashid Sayyid and Zach Klaassen, dissect a publication from the VISION study regarding health-related quality of life and pain outcomes with Lu-PSMA-617+ Standard of Care versus Standard of Care alone in patients with mCRPC. This study, conducted across 84 global centers, reveals that the addition of Lu-PSMA-617 to standard care significantly improved overall survival rates from 11.3 to 15.3 month...
|
- Details
- Rashid Sayyid and Zach Klaassen shed light on the TALAPRO-2 study published in The Lancet. This study evaluated the combination of talazoparib, a potent PARP inhibitor, and enzalutamide in treating men with first-line metastatic castration-resistant prostate cancer (mCRPC). They note the poor prognosis for patients with mCRPC and the need for more effective treatments, especially for those with ho...
|
